| Status | In progress |
| Decision | Selected |
| Process | TA |
| ID number | 1056 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TACommD@nice.org.uk
Stakeholders
| Companies sponsors | Bayer |
| Others | Department of Health |
| NHS England | |
| Welsh Government | |
| Patient carer groups | GIST Support Group |
| Sarcoma UK | |
| Professional groups | Cancer Research UK |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
| National Cancer Research Institute |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 November 2017 | Expected publication |
| 12 October 2017 - 26 October 2017 | Final appraisal determination |
| 30 August 2017 | Committee meeting: 2 |
| 02 August 2017 | Following the recent discussion on 28 June, the committee concluded that it needed more information from the company before it can make a decision. Given the information is related to the technical aspects of the economic analysis, we will not be issuing any documentation at this stage. The committee will consider the additional information at its meeting on Wednesday 30 August 2017 and continue its deliberations on regorafenib for gastrointestinal stromal tumours. |
| 28 June 2017 | Committee meeting: 1 |
| 20 January 2017 | Invitation to participate |
| 20 September 2016 | Draft scope documents |
| 08 June 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual